Financial health
- Operating income covered interest expense -24.2× in the latest year.
NRXP Financials NRX Pharmaceuticals, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$29M | 58.8% | -1324.4% | — | — | $8M |
| 2024 | $0 | -$25M | — | — | -$11M | — | $1M |
| 2023 | — | -$30M | — | — | -$22M | $9M | $5M |
| 2022 | — | -$40M | — | — | -$40M | $11M | $20M |
| 2021 | — | -$93M | — | — | -$38M | — | $28M |
| 2020 | — | -$52M | — | — | -$2M | — | — |
| 2019 | — | $408427 | — | — | — | — | — |
| 2018 | — | $66101 | — | — | — | — | — |
| 2018 | — | -$1187 | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$1M | 40.9% | -444.0% | — | — | $7M |
| Sep '25 | $242000 | -$6M | 59.9% | -1662.8% | — | — | $7M |
| Jun '25 | $0 | -$18M | — | — | — | — | $3M |
| Mar '25 | $0 | -$6M | — | — | -$3M | — | $6M |
| Dec '24 | $0 | -$9M | — | — | -$2M | — | $1M |
| Sep '24 | $0 | -$2M | — | — | -$2M | — | $2M |
| Jun '24 | — | -$8M | — | — | -$3M | — | $2M |
| Mar '24 | — | -$7M | — | — | -$4M | — | $1M |
| Dec '23 | — | -$4M | — | — | -$3M | $9M | $5M |
| Sep '23 | — | -$6M | — | — | -$5M | $10M | $9M |
| Jun '23 | — | -$9M | — | — | -$8M | $13M | $15M |
| Mar '23 | — | -$11M | — | — | -$6M | $12M | $17M |
| Dec '22 | — | -$10M | — | — | -$8M | $11M | $20M |
| Sep '22 | — | -$9M | — | — | -$6M | — | $18M |
| Jun '22 | — | -$7M | — | — | -$15M | — | $25M |
| Mar '22 | — | -$13M | — | — | -$10M | — | — |
| Dec '21 | — | -$30M | — | — | -$11M | — | $28M |
| Sep '21 | — | -$37M | — | — | -$12M | — | — |
| Jun '21 | — | -$117000 | — | — | — | — | — |
| Mar '21 | — | -$25M | — | — | — | — | — |
Valuation over time
How the market has priced NRXP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 79.6× (Dec '25) to 103.5× (Jun '26).
P/S
Frequently asked questions
Is NRXP growing its revenue and profit?
See the revenue and net-income charts above for NRX Pharmaceuticals, Inc.'s multi-year trend.
How much debt does NRXP have?
As of FY2025, NRX Pharmaceuticals, Inc. reported — of total debt against $8M of cash; operating income covered interest expense -24.2×.
What is NRXP's profit margin?
In FY2025, gross margin was 58.8%, operating margin -1324.4%, and net margin -2336.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.